Introduction
============

Coronary artery disease (CAD) is a common clinical cardiovascular disease ([@b1-etm-0-0-8299]). The American Heart Association has reported that in 2016 the number of CAD patients ≥20 years of age had reached 15.5 million and the incidence increased with age ([@b2-etm-0-0-8299]). At present, the pathogenesis of CAD is not completely clear, however it is certain that hypertension, diabetes, obesity and dyslipidemia are risk factors for the onset of CAD ([@b3-etm-0-0-8299],[@b4-etm-0-0-8299]). As people\'s living standards and dietary habits change, unhealthy diets lead to an increasing number of obese patients. A study has shown that visceral obesity patients develop CAD more rapidly and suffer a higher incidence of acute myocardial infarction ([@b5-etm-0-0-8299]). In addition, the risk of developing CAD is not the same for individuals with the same body fat, which is mainly caused by the different distribution of body fat ([@b6-etm-0-0-8299]).

Epicardial fat is a kind of adipose tissue, which promotes remodeling of coronary artery. It has been reported that the development of CAD is closely related to epicardial fat and its volume change is an important index for the severity of CAD ([@b7-etm-0-0-8299]). At present, the gold standard for epicardial fat volume detection is magnetic resonance imaging (MRI), multislice computed tomography (MSCT) and other imaging methods ([@b8-etm-0-0-8299]). MRI and MSCT have a relatively long detection time and high cost, while serological detection is less expensive and requires shorter time than MRI and MSCT ([@b9-etm-0-0-8299]). Therefore, it is critical to find serum indexes to reflect the changes in the epicardial fat volume of patients. Adiponectin is a protein secreted by adipocyte, which can regulate glucose metabolism, improve insulin resistance and fight atherosclerosis, and is expressed obviously lower in the serum of CAD patients ([@b10-etm-0-0-8299]). Chemerin belongs to the adipocyte-factor family, which has the function of leukocyte chemotaxis and can promote the development of inflammatory response in injured tissues by recruiting inflammatory cells of chemerin receptors ([@b11-etm-0-0-8299]). Vascular endothelial growth factor (VEGF) is a vascular endothelial cell mitogen with high specificity, which plays an important regulatory role in angiogenesis and is highly expressed in the serum of CAD patients ([@b12-etm-0-0-8299]). However, it is unclear whether adiponectin, chemerin and VEGF can be adopted as observation indexes for changes in the epicardial fat volume.

The present study explored the correlation of adiponectin, chemerin, and VEGF with epicardial fat volume of CAD patients and its potential clinical value to provide a reference for clinicians in diagnosis and treatment.

Subjects and methods
====================

### Clinical data

A total of 50 CAD patients, treated in Chongzuo People\'s Hospital (Chongzuo, China) from August 2017 to September 2018, were enrolled as the observation group, and additional 50 healthy subjects, who underwent physical examination in the hospital at the same period, were enrolled as the control group. Subjects in the control group exhibited normal values in all clinical laboratory detection tests and were without combined congenital organ dysfunction. This study was conducted with the approval of the medical Ethics Committee of Chongzuo People\'s Hospital. Inclusion criteria: All patients included met the criteria of the 2012 USA Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease ([@b13-etm-0-0-8299]). The patients and their families understood the purpose of the study, and an informed consent was signed. Patients were diagnosed with CAD by imaging and their clinical data were complete. Exclusion criteria: Patients with angina pectoris, silent myocardial ischemia, heart failure, arrhythmia, and sudden death; patients with abnormal thyroid function, infectious diseases or tumors; patients with recent trauma or history of surgery; pregnant women; patients with hepatic and kidney function obstacle.

### Reagents and instruments

EasyPure Blood RNA kit, TransScript II Green Two-Step qRT-PCR SuperMix (both from Beijing TransGen Biotech Co., Ltd.; ER101-01 and AQ301-01, respectively), adiponectin, chemerin and VEGF primers, and related sequences (all designed and synthesized by Shanghai GenePharma Co., Ltd.), PCR instrument (Applied Biosystems; Thermo Fisher Scientific, Inc.; ABI 7500) and 64-slice dual-source CT instrument (Siemens AG; SOMATOM Definition Flash).

Methods
-------

### Collection of peripheral blood and RT-qPCR detection

The study participants fasted from 8 p.m. on the day before the test. Peripheral venous blood (5 ml) was collected from both groups in the morning. Following standing for 30 min, the blood was centrifuged at 1,500 × g, at 25°C for 10 min. The supernatant was collected for PCR detection, and the total RNA of the collected serum was extracted using the EasyPure Blood RNA kit. Total RNA purity, concentration and integrity of the extracted total RNA were detected via ultraviolet spectrophotometry and agarose gel electrophoresis. Reverse transcription was performed by 5X TransScript^®^ II All-in-One SuperMix for qPCR and gDNA Remover kit (both from Beijing TransGen Biotech Co., Ltd.) in strict accordance with the manufacturer\'s instructions. The reaction system consisted of 1 µg of total RNA, 4 µg of 5X TransScript^®^ II All-in-One SuperMix, 1 µg of gDNA Remover, and RNase-free Water (added for a total of 20 µl). The reaction conditions were as follows: Incubation at 50°C for 15 min, and at 85°C for 5 sec. Then, PCR amplification was carried out. PCR reaction system: 1 µl of cDNA, 0.4 µl of upstream primers and 0.4 µl of downstream primers, 10 µl of 2X TransScript^®^ Tip Green qPCR SuperMix, Passive Reference Dye (50X) and Nuclease-free Water (added for a total volume of 20 µl) (all from Beijing TransGen Biotech Co., Ltd.). PCR reaction conditions: Initial denaturation at 94°C for 30 sec, denaturation at 94°C for 5 sec and annealing and extending at 60°C for 30 sec for a total of 40 cycles ([@b14-etm-0-0-8299]). The upstream and downstream primers of adiponectin were 5′-GCATTCAGTGTGGGATTGGAG-3′ and 5′-AGACTGTGATGTGGTAGGCAAAG-3′, respectively; the upstream and downstream primers of chemerin were 5′-AAACCCGAGTGCAAAGTCAG-3′ and 5′-CCGCAGAACTTGGGTCTCTAT-3′, respectively; the upstream and downstream primers of VEGF were 5′-GAAGGTGAAGGTCGGAGTC-3′ and 5′-TGGTTCCCGAAACGCTGAG-3′, respectively, and the upstream and downstream primers of GAPDH were 5′-GAAGGTGAAGGTCGGAGTC-3′ and 5′-GAAGATGGTGATGGGATTTC-3′, respectively. Three multiple pores were set for each sample, and the experiment was carried out 3 times. GAPDH was the internal reference, and 2^−ΔΔCq^ ([@b14-etm-0-0-8299]) was used to analyze the data.

### Epicardial fat volume detection

Participants in both groups were subjected to 64-slice dual-source CT detection, and their epicardial fat volume was detected by Volumer software (GE Healthcare). Contrast agent was injected intravenously at 5--10 min before detection, and nitroglycerin and metoprolol were administered orally to dilate vessels and control the heart rate. Tissues with −250 to −30 HU in CT were set as adipose tissues. The cardiac fiber membrane identifiable from the lower apical edge in the left ventricular at the origin of the left pulmonary artery of newly transverse sinus midpoint was selected (namely the cardiac membrane boundary), and it was selected at intervals of 0.5--1.0 cm layer by layer. Finally the fat volume was calculated using the Volumer software.

### Vascular remodeling detection

Contrast examination was performed on the left and right coronary arteries of all participants. According to the data obtained from the 64-slice dual-source CT detection, the vascular remodeling index of the observation group was calculated: Vascular remodeling index = (external elastic membranous area at lesions)/(vascular area at reference site). At vascular remodeling index ≥1 the patient developed remodeling.

### Observation indexes

Main observation indexes: The two groups were compared in expression of adiponectin, chemerin and VEGF in serum, and in epicardial fat volume, and the correlation of adiponectin, chemerin, and VEGF with epicardial fat volume in the observation group was analyzed. Secondary observation indexes: The two groups were compared in clinical data, and vascular remodeling of patients in the observation group was observed and analyzed; risk factors for vascular remodeling in CAD patients were analyzed, and receiver operating characteristic (ROC) curve analysis was adopted to analyze the value of indexes with multivariate significance in vascular remodeling.

### Statistical analysis

Collected data were analyzed by SPSS 20.0 software (IBM Corp.), relevant graphs were created using GraphPad Prism 7 software (GraphPad Software, Inc.), and the distribution of data was analyzed using the Kolmogorov-Smirnov test. Enumeration data were expressed as n (%), and analyzed using Chi-square (χ^2^) test. Measurement data were expressed as the mean ± standard deviation (mean ± SD). Data in normal distribution were subjected to t-test and were expressed by a t value. Comparisons between groups were performed using the independent samples t-test. Multivariate logistic regression was adopted to analyze the risk factors for vascular remodeling. ROC analysis was adopted to map the areas under the independent risk factor curves. Pearson\'s correlation analysis was used to analyze the correlation of adiponectin, chemerin, and VEGF with epicardial fat volume in the observation group. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinical data analysis

The clinical data of the two groups were collected for analysis. There was no statistical significance between the two groups in sex, age, body mass index (BMI), family history of CAD, smoking history, alcohol abuse history and place of residence (all P\>0.05) ([Table I](#tI-etm-0-0-8299){ref-type="table"}).

### Epicardial fat volume of the two groups

Epicardial fat volume of the two groups was detected, and it was found that the observation group showed obviously larger epicardial fat volume than the control group (189.22±29.08 vs. 132.48±23.42 cm^3^) (P\<0.001) ([Fig. 1](#f1-etm-0-0-8299){ref-type="fig"}).

### Expression of adiponectin, chemerin and VEGF in the two groups

The expression of adiponectin, chemerin and VEGF in the two groups was compared, and it was found that the observation group showed obviously lower adiponectin expression than the control group, with a significant difference (P\<0.001), and obviously higher expression of chemerin and VEGF than the control group, with a significant difference (both P\<0.001) ([Fig. 2](#f2-etm-0-0-8299){ref-type="fig"}).

### Correlation of adiponectin, chemerin and VEGF with epicardial fat volume in the observation group

Pearson\'s correlation analysis showed that in the observation group, the adiponectin expression gradually decreased with the increase of epicardial fat volume, presenting a negative correlation (P\<0.001), and the expression levels of chemerin and VEGF gradually increased with the increase of epicardial fat volume presenting a positive correlation (both P\<0.001) ([Fig. 3](#f3-etm-0-0-8299){ref-type="fig"}).

### Analysis of risk factors for vascular remodeling in the observation group

Statistical analysis of vascular remodeling in the observation group showed that 27 of the 50 patients developed remodeling, and the patients were divided into a remodeling group (n=27) and a non-remodeling group (n=23). Clinical data of patients were collected for univariate analysis, and it was found that adiponectin, chemerin, VEGF and epicardial fat volume were risk factors for vascular remodeling (all P\<0.05). Subsequently, remodeling of patients was used as the independent variable and factors with significance in univariate analysis were taken as covariate, and assignment was performed. Binary logistic regression was performed and forward logistic regression was adopted to analyze the results. It was found that epicardial fat volume (OR: 6.945, 95% CI: 1.385--34.825), adiponectin (OR: 0.124, 95% CI: 0.022--0.689), chemerin (OR: 5.175, 95% CI: 1.079--24.834) and VEGF (OR: 12.752, 95% CI: 2.146--75.760) were independent risk factors for vascular remodeling in CAD patients ([Tables II](#tII-etm-0-0-8299){ref-type="table"}--[IV](#tIV-etm-0-0-8299){ref-type="table"}).

### Multivariate ROC curve analysis

A ROC curve was drawn for indexes with multifactorial significance. It was found that the areas under adiponectin, chemerin, VEGF and epicardial fat volume curves were 0.697, 0.652, 0.696, and 0.689, respectively ([Table V](#tV-etm-0-0-8299){ref-type="table"} and [Fig. 4](#f4-etm-0-0-8299){ref-type="fig"}).

Discussion
==========

Epicardial adipose tissue is a relatively unique visceral adipose tissue between myocardium and pericardium. According to previous studies, there is a close relationship between epicardial adipose tissue and vascular remodeling and atherosclerosis ([@b15-etm-0-0-8299]), and epicardial adipose tissue can be adopted as an independent risk factor for coronary artery stenosis and plaque vulnerability ([@b16-etm-0-0-8299]). However, epicardial fat volume is mainly detected through imaging in clinic, which may aggregate the burden of patients due to its long imaging time and high cost. Compared with imaging, serological detection has the advantages of requiring shorter time and have low cost. Therefore, it is critical to find serum indexes to reflect changes in the epicardial fat volume of patients.

The epicardial fat volumes of the observation and control groups were first detected showing that the observation group had obviously larger epicardial fat volume than the control group. Previous studies have shown that epicardial fat accumulates during the development of CAD, which may cause the release of a large number of epicardial adipose cell cytokines and inflammatory factors, promoting calcified plaque in coronary artery, leading eventually to coronary artery occlusion in patients ([@b17-etm-0-0-8299],[@b18-etm-0-0-8299]). Therefore, the question is whether adipocyte factors or vascular factors related to CAD can be detected to determine the epicardial fat volume of patients. To find the answer, adiponectin, chemerin and VEGF in the serum of CAD patients were detected. A study conducted by Eiras and González-Juanatey ([@b19-etm-0-0-8299]) showed that low adiponectin expression in CAD patients is expected to be a potential biomarker for CAD, while a study conducted by Madonna *et al* ([@b20-etm-0-0-8299]) and Nakamura *et al* ([@b21-etm-0-0-8299]) showed that both chemerin and VEGF have the effect of promoting blood vessel survival. The present study detected the expression of adiponectin, chemerin and VEGF in the serum of the observation group, finding that the expression of chemerin and VEGF in the serum of the observation group was significantly higher than those of the control group, while the expression of adiponectin was significantly lower than that of the control group, in consistency with previous studies ([@b22-etm-0-0-8299],[@b23-etm-0-0-8299]). The present study further detected and analyzed the correlation of adiponectin, chemerin, and VEGF with epicardial fat volume by performing a Pearson\'s correlation analysis. The results revealed that adiponectin expression gradually decreased with the increase of epicardial fat volume, showing a negative correlation, while the expression of chemerin and VEGF gradually increased with the increase of epicardial fat volume, showing a possitive correlation. This suggests that adiponectin, chemerin, and VEGF could be taken as potential observation indexes for changes in epicardial fat volume. The relevant mechanisms of indexes and epicardial fat volume may be the following: i) Both adiponectin and chemerin can be produced by epicardial adipose tissue. The accumulation of epicardial fat in patients after CAD will cause the release of a large number of inflammatory factors and adipocyte factors, promoting CAD ([@b24-etm-0-0-8299]). ii) VEGF is an angiogenic growth factor. When a body is hypoxic-ischemic, VEGF expression will significantly increase, which will alleviate myocardial apoptosis induced by myocardial ischemia by promoting angiogenesis and collateral circulation; while with the increase of epicardial fat volume and gradual aggravation of CAD, VEGF expression in serum increases ([@b25-etm-0-0-8299]).

Statistics on remodeling of CAD patients was performed. Vascular remodeling is a morphological change in the lumen for the change of structure of the patient\'s vascular wall. Vascular remodeling can cause endothelial cell proliferation, inflammatory cell aggregation and increase of atherosclerosis area ([@b26-etm-0-0-8299]). Therefore, it is especially important to explore the risk factors for vascular remodeling. We conducted multivariate analysis, finding that increase of epicardial fat volume, chemerin and VEGF and decrease of adiponectin are independent risk factors for vascular remodeling, and we mapped ROC curves, finding that each index has a certain clinical diagnostic value in vascular remodeling.

The present study can preliminarily explain the correlation between adiponectin, chemerin, VEGF and epicardial fat volume of CAD patients, and the expression of adiponectin, chemerin and VEGF can reflect epicardial fat volume in CAD patients. Epicardial fat volume, adiponectin, chemerin and VEGF can be adopted as potential observation indexes of vascular remodeling. However, this study still has certain limitations. ROC curves of adiponectin, chemerin, and VEGF in CAD patients were not drawn and expression of adiponectin, chemeri and VEGF in adipose tissue of CAD patients were not detected. Therefore, further study is still required.

In summary, epicardial fat volume, adiponectin, chemerin and VEGF are independent risk factors for vascular remodeling, and the expression of adiponectin, chemerin and VEGF can reflect the epicardial fat volume.
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![Comparison of the expression of adiponectin, chemerin and VEGF between the observation and control group. (A) Comparison of adiponectin expression between the observation group (0.631±0.194) and the control group (1.026±0.117) (t=12.315, P\<0.001). (B) Comparison of chemerin expresion between the observation group (1.571±0.220) and the control group (1.082±0.129) (t=13.576, P\<0.001). (C) Comparison of VEGF expression between the observation group (1.674±0.198) and the control group (1.043±0.116) (t=19.432, P\<0.001). \*\*\*P\<0.001. VEGF, vascular endothelial growth factor..](etm-19-02-1095-g01){#f2-etm-0-0-8299}

![Correlation of the expression of adiponectin, chemerin, and VEGF with epicardial fat volume in the observation group. Epicardial fat volume was (A) negatively correlated with adiponectin (r=−0.549, P\<0.001), and positively correlated with (B) chemerin (r=0.696, P\<0.001) and (C) VEGF (r=0.667, P\<0.001). VEGF, vascular endothelial growth factor.](etm-19-02-1095-g02){#f3-etm-0-0-8299}

![ROC curves. Red line represents adiponectin, blue line represents chemerin, green line represents VEGF, and the brown line represents epicardial fat volume. ROC, receiver operating characteristic; VEGF, vascular endothelial growth factor.](etm-19-02-1095-g03){#f4-etm-0-0-8299}

###### 

Comparison of baseline data between the two groups \[n (%), mean ± SD\].

  Factors                 Observation group (n=50)   Control group (n=50)   t/χ^2^   P-value
  ----------------------- -------------------------- ---------------------- -------- ---------
  Sex                                                                       1.099    0.295
    Male                  35 (70.00)                 30 (60.00)                      
    Female                15 (30.00)                 20 (40.00)                      
  Age (years)             60.1±8.4                   59.7±9.2               0.227    0.821
  BMI (kg/m^2^)           25.74±2.84                 24.79±2.25                      
  Family history of CAD                                                     3.241    0.072
    Yes                   20 (40.00)                 29 (58.00)                      
    No                    30 (60.00)                 21 (42.00)                      
  Smoking history                                                           0.713    0.398
    Yes                   35 (70.00)                 31 (62.00)                      
    No                    15 (30.00)                 19 (38.00)                      
  Alcohol abuse history                                                     0.749    0.102
    Yes                     5 (10.00)                  6 (12.00)                     
    No                    45 (90.00)                 44 (88.00)                      
  Place of residence                                                        0.694    0.405
    City                  30 (60.00)                 34 (68.00)                      
    Country               20 (40.00)                 16 (32.00)                      

BMI, body mass index; CAD, coronary artery disease.

###### 

Univariate analysis of risk factors for vascular remodeling \[n (%), mean ± SD\].

  Factors                         Patients in the remodeling group (n=27)   Patients in the non-remodeling group (n=23)   t/χ^2^   P-value
  ------------------------------- ----------------------------------------- --------------------------------------------- -------- ---------
  Sex                                                                                                                     0.004    0.951
    Male                          19 (70.37)                                16 (69.57)                                             
    Female                          8 (29.63)                                 7 (30.43)                                            
  Age (years)                                                                                                             0.080    0.777
    ≥60                           13 (48.15)                                12 (52.17)                                             
    \<60                          14 (51.85)                                11 (47.83)                                             
  BMI (kg/m^2^)                                                                                                           0.415    0.520
    ≥24                           22 (81.48)                                17 (73.91)                                             
    \<24                            5 (18.52)                                 6 (26.09)                                            
  Family history of CAD                                                                                                   0.215    0.643
    Yes                           10 (37.04)                                10 (43.48)                                             
    No                            17 (62.96)                                13 (56.52)                                             
  Smoking history                                                                                                         0.004    0.951
    Yes                           19 (76.00)                                16 (69.57)                                             
    No                              8 (24.00)                                 7 (30.43)                                            
  Alcohol abuse history                                                                                                   0.438    0.508
    Yes                             2 (7.41)                                  3 (13.04)                                            
    No                            25 (92.59)                                20 (86.96)                                             
  Place of residence                                                                                                      0.483    0.487
    City                          15 (55.56)                                15 (65.22)                                             
    Country                       12 (44.44)                                  8 (34.78)                                            
  Adiponectin                       0.563±0.148                               0.710±0.214                                 2.858    0.006
  Chemerin                          1.638±0.240                               1.504±0.207                                 2.094    0.042
  VEGF                              1.735±0.161                               1.601±0.215                                 2.516    0.015
  Epicardial fat volume (cm^3^)   198.57±27.11                              178.25±27.95                                  2.604    0.012

BMI, body mass index; CAD, coronary artery disease; VEGF, vascular endothelial growth factor.

###### 

Valuation.

  Factors                 Valuation
  ----------------------- -----------------------------------
  Epicardial fat volume   ≥189.22 cm^3^=1, \<189.22 cm^3^=0
  Adiponectin             ≥0.631=1, \<0.631=0
  Chemerin                ≥1.571=1, \<1.571=0
  VEGF                    ≥1.674=1, \<1.674=0
  Remodeling              Remodeling =1, non-remodeling =0

VEGF, vascular endothelial growth factor.

###### 

Multivariate analysis.

                                                                    95% CI of Exp (β)   
  ----------------------- -------- ------- ------- ------- -------- ------------------- --------
  Adiponectin             −2.089   0.876   5.692   0.017   0.124    0.022               0.689
  Chemerin                1.644    0.800   4.221   0.040   5.175    1.079               24.834
  VEGF                    2.546    0.909   7.840   0.005   12.752   2.146               75.760
  Epicardial fat volume   1.938    0.823   5.551   0.018   6.945    1.385               34.825

VEGF, vascular endothelial growth factor.

###### 

ROC parameters.

  Factors         Adiponectin    Chemerin       VEGF           Epicardial fat volume
  --------------- -------------- -------------- -------------- -----------------------
  AUC             0.697          0.652          0.696          0.689
  95% CI          0.548--0.846   0.500--0.804   0.547--0.844   0.542--0.836
  Sensitivity     77.78%         29.63%         62.96%         88.88%
  Specificity     60.87%         95.65%         73.91%         43.48%
  Youden index    38.65%         25.28%         36.88%         32.37%
  Cut-off value   \<0.661        \>1.837        \>1.694        \>168.91

ROC, receiver operating characteristic; VEGF, vascular endothelial growth factor.
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